136 completed, 8 recruiting, 8 terminated, 4 not yet recruiting. 66 Phase 1, 48 Phase 3, 42 Phase 2, 5 Phase 4, 2 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 1 | 66 | Completed 57, Recruiting 4, Not yet recruiting 3, Terminated 1, Unknown 1 |
| Phase 3 | 48 | Completed 43, Terminated 3, Recruiting 2 |
| Phase 2 | 42 | Completed 27, Recruiting 5, Terminated 4, Active not recruiting 2, Not yet recruiting 2, Unknown 2 |
| Phase 4 | 5 | Completed 5 |
| Not applicable | 2 | Completed 2 |
Follow Shionogi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD) S-606001, ERT - Pompe Disease | Phase 2 | Not yet recruiting | 60 | 2027-03-31 | 2026-11-18 |
A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD) S-606001 - Pompe Disease | Phase 1 | Not yet recruiting | 15 | 2026-11-30 | 2026-11-17 |
Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls Sulthiame - Renal Impairment | Phase 1 | Not yet recruiting | 30 | 2026-09-29 | 2026-10-05 |
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Secutrelvir, Placebo - SARS-CoV-2 | Phase 3 | Recruiting | 2000 | 2026-09-14 | 2026-11-17 |
Study of Secutrelvir in Participants With COVID-19 Secutrelvir, Placebo - COVID-19 | Phase 3 | Recruiting | 1200 | 2026-08-05 | 2026-09-02 |
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer S-531011, Fruquintinib, Pembrolizumab - Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | 68 | 2026-05-01 | 2026-05-18 |
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease S-337395, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Recruiting | 192 | 2025-12-11 | 2026-10-21 |
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) S-606001, Placebo - Pompe Disease | Phase 2 | Recruiting | 45 | 2025-10-30 | 2026-06-23 |
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls S-892216-PO - Renal Impairment | Phase 1 | Completed | 24 | 2025-10-16 | 2026-10-22 |
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls BPN14770 - Hepatic Impairment | Phase 1 | Completed | 32 | 2025-08-30 | 2026-02-27 |
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls BPN14770 - Renal Impairment | Phase 1 | Completed | 14 | 2025-08-25 | 2026-02-27 |
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants S-892216-LAI, Placebo - Healthy Participants | Phase 1 | Recruiting | 128 | 2025-07-29 | 2026-10-16 |
A Study to Assess the Effects of BPN14770 on Rosuvastatin Rosuvastatin, BPN14770 - Healthy Participants | Phase 1 | Completed | 12 | 2025-07-18 | 2025-08-14 |
Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study Naldemedine, Placebo - Opioid-Induced Nausea and Vomitting(OINV) | Phase 4 | Completed | 120 | 2025-06-20 | 2026-06-03 |
A Study of S-892216 in Participants With COVID-19 S-892216, Placebo - COVID-19 | Phase 2 | Completed | 282 | 2025-06-06 | 2026-09-21 |
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) BPN14770, Placebo - Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder | Phase 2 | Active not recruiting | 30 | 2025-05-13 | 2026-06-09 |
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea Sivopixant, Placebo, Acetazolamide - Sleep Apnea | Phase 2 | Active not recruiting | 60 | 2025-04-02 | 2026-05-06 |
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants Ensitrelvir - Healthy Adult Female Participants | Phase 1 | Completed | 24 | 2024-12-30 | 2025-05-04 |
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants S-892216, Carbamazepine - COVID-19 | Phase 1 | Completed | 16 | 2024-12-17 | 2025-03-11 |
A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants RSV Infections | | Completed | 100 | 2024-12-09 | 2025-05-04 |
Showing 20 of 162. Sign in to see all of them.
Conditions studied
Infections (25) · Acquired Immunodeficiency Syndrome (23) · HIV Infections (11) · COVID-19 (7) · Obesity (7) · Amyotrophic Lateral Sclerosis (6) · Atrophy (6) · Opioid-Induced Constipation (6) · Vaginal Diseases (6) · Renal Insufficiency (5) · Ischemic Stroke (4) · Sepsis (4) · Carcinoma, Non-Small-Cell Lung (3) · Esophageal Neoplasms (3) · Glycogen Storage Disease (3)
Interventions
dolutegravir (31) · Edaravone (24) · Cefiderocol (11) · Duloxetine Hydrochloride (11) · naldemedine (8) · Ospemifene (7) · ensitrelvir (5) · BPN14770 (4) · Midazolam (4) · Rosuvastatin Calcium (4) · Standard of Care (3) · Tablets (3) · abacavir (3) · baloxavir (3) · cabotegravir (3)
Countries
United States (96) · Japan (50) · Spain (16) · Germany (14) · United Kingdom (14) · Canada (13) · France (13) · Italy (13) · Belgium (9) · Australia (8) · Taiwan (7) · Czechia (6) · Hungary (6) · Poland (6) · South Africa (6)
Top investigators
Hiroshi Shiku, M.D., Ph.D. (2) · Shinichi Kageyama, M.D., Ph.D. (2) · Yataro Daigo, MD, PhD (2) · David Paterson, Professor (1)
Results publications
PMID 32086791, PMID 32280263, PMID 34295186, PMID 34792787, PMID 35585696, PMID 36376130, PMID 39230271, PMID 28576452, PMID 31145214, PMID 32800532, PMID 33393598, PMID 33704925, PMID 33965574, PMID 34377150, PMID 35076335, PMID 37619252, PMID 37953075, PMID 17404091, PMID 19321945, PMID 22298950, PMID 22831708, PMID 23361170, PMID 23817375, PMID 23979733, PMID 24074642, PMID 24096683, PMID 24135530, PMID 24195548, PMID 24446523, PMID 24798770, PMID 24838177, PMID 24944232, PMID 25286015, PMID 25321146, PMID 26262777, PMID 26296539, PMID 26816607, PMID 28371937, PMID 28522181, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 28919811, PMID 29030478, PMID 29713194, PMID 30126675, PMID 30184455, PMID 30271191
NIH funding
2019 (4), 2016 (2), 2018 (2), 2009 (1), 2014 (1), 2015 (1), 2023 (1), 2025 (1)